Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection

ConditionsCOVID19 Influenza Vaccination ACE Inhibitors ARB Antihistamine Allergy Amantadine

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

AgeNot listed

SponsorConsorci Sanitari de Terrassa

About this trial

Some authors have proposed the use of the flu vaccine to reduce the severity of COVID-19 cases, while some have proposed the use of ACE Inhibitors (ACEI) or Angiotensin Receptor blockers (ARB), since this virus shares hemagglutinin as a transmission mechanism and acts on the ACE2 enzyme during infection.

Other authors described how none of the elderly patients receiving antihistamines and azythromycin in two nursing homes in Toledo -Spain- during the first wave died or needed hospital admission, even considering that 100% of residents had a positive serological test after that wave. Other authors have described a positive evolution in patients receiving amantadine for their Parkinson's disease.

The aim is to evaluate whether the admitted patients who are previously vaccinated or those who were already receiving these treatments showed a better evolution.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Hospital Admissions at the Hospital of Terrassa from March 1, 2020 for any cause.

Disqualifiers

None.

For comparison of percentage of Influenza vaccination, ACEI and ARB vs general population, patients from outside the reference area of the Terrassa Health Consortium would be excluded.

Trial population

All hospital admissions in the Hospital of Terrassa from March 1, 2020 were innitially included. Population of reference: the population assigned to the Terrassa Health Consortium population.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Antihistamine
Drug
No intervention is performed. We propose an observational study.
Amantadine
Drug
No intervention is performed. We propose an observational study
ACEI
Drug
No intervention is performed. We propose an observational study.
ARB
Drug
No intervention is performed. We propose an observational study.
Influenza vaccine and COVID
Other intervention
No intervention is performed. We propose an observational study.

Treatment groups

3,000 Participants

are divided into 3 treatment groups

Group A: Hospital admissions, postcovid syndrome and thrombosis among COVID cases in CST population5 interventions

Group B: Evolution of COVID cases in patients receiving antihistamines1 intervention

Group C: Evolution of COVID cases in patients receiving amantadine.1 intervention

Trial outcomes

Primary outcomes

hospital output

exitus vs hospital output

Time frame

from March 1, 2020.

Secondary outcomes

hospital stay

length of the hospital stay

Time frame

From March 1, 2020.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Consorci Sanitari de Terrassa

Lead sponsor

Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina

Collaborator

Institut Català de la Salut